Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neovascular Age-related Macular Degeneration (nAMD): full-pipeline trial registry
5 of 10 indexed Neovascular Age-related Macular Degeneration (nAMD) trials are currently recruiting.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Neovascular Age-related Macular Degeneration (nAMD): 10 US clinical trials tracked, 5 recruiting.
Neovascular Age-related Macular Degeneration (nAMD) is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Adverum Biotechnologies, running 2 of these trials.
Enrollment posture brief
Registry condition neovascular-age-related-macular-degeneration-namd
OPEN 5 | RECR 50% | LATE 6 | EARLY 4 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Neovascular Age-related Macular Degeneration (nAMD) lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neovascular Age-related Macular Degeneration (nAMD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neovascular Age-related Macular Degeneration (nAMD) is recruiting above its size-band peers.
5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neovascular Age-related Macular Degeneration (nAMD) research.
Adverum Biotechnologies accounts for 2 of 10 trials (20%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Neovascular Age-related Macular Degeneration (nAMD) enrolment sits around 180 participants.
Median target enrolment is 180 among the 10 trials that report a genuine target (sentinel values excluded). 3 of those (30%) plan for fewer than 100 participants.
-
Neovascular Age-related Macular Degeneration (nAMD) research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics
NCT07064759
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Adverum Biotechnologies
NCT07482176
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Adverum Biotechnologies
NCT06856577
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Alcon Research
NCT05769153
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
Ocugenix Corporation
NCT05904691
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche
NCT06795048
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
Kyowa Kirin Co.
NCT06116890
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
AbbVie
NCT04514653
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
Sandoz
NCT05282004
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
Sandoz
NCT05161806
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neovascular Age-related Macular Degeneration (nAMD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neovascular Age-related Macular Degeneration (nAMD) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neovascular Age-related Macular Degeneration (nAMD) page
10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Neovascular Age-related Macular Degeneration (nAMD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Adverum Biotechnologies sponsors the most Neovascular Age-related Macular Degeneration (nAMD) trials on record, review their full trial history before evaluating a specific study. See Adverum Biotechnologies's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neovascular Age-related Macular Degeneration (nAMD) condition card totals 10 registered trials; most-linked intervention Aflibercept; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.